Contova^®

Contova is a preparation of Olopatadine Hydrochloride. Olopatadine principally acts as a selective histamine H1 receptor antagonist. It also inhibits the production and release of chemical mediators (leukotriene, thromboxane, PAF etc.) and the release of the neurotransmitter tachykinin.

No Data

Contova is indicated in the treatment of allergic rhinitis, urticaria, itching resulting from skin diseases in adults and in children.

Route of administration:

Contova should be taken in oral route with or without food. Administer 5 mg tablet twice a day orally in the morning and at bedtime in adults and children over 7 years of age.
The dose may be increased or decreased according to age and symptoms.

Pregnancy: There are no studies with olopatadine use in pregnant women to inform a drug-associated risk.

Lactation: If treatment with olopatadine is essential during lactation, breast feeding must be discontinued during treatment.

Use in children and adolescents
Safety and effectiveness of olopatadine in low-birth-weight babies, newborns and sucklings or infants has not been established.

Caution should be taken in patients with impaired renal function. Since olopatadine may induce drowsiness, patients should be cautioned against engaging in potentially hazardous activities. In case olopatadine is administered in the patients who have been under chronic treatment with a steroid, dose reduction of the steroid should be made gradually. In the patients with seasonal diseases, it is recommended to initiate administration immediately before the typical season to be continued until the end of the season. If olopatadine dose not exhibit effect, administration should not be continued aimlessly for a prolonged time. There’s risk of myocardial infarction following administration.

The most common side effects are sleepiness, increased ALT & AST, malaise and thirst.

It is contraindicated in patients with history of known hypersensitivity to olopatadine or any other components of this product.

Drug interaction with medication: No significant drug interaction has been reported.
Drug interaction with food and others: Not applicable.

In the event of overdose, general supportive measures and proper monitoring should be initiated.

No Data

No Data

Contova 2.5 Tablet: Each coated tablet contains Olopatadine Hydrochloride USP 2.5 mg.

Contova 5 Tablet: Each coated tablet contains Olopatadine Hydrochloride USP 5 mg

Storage
Store below 30°C in a dry place, protected from light. Keep away from the reach of children.

Packing
Contova 2.5 Tablet: Each box contains 30 tablets in blister pack.
Contova 5 Tablet: Each box contains 30 tablets in blister pack.